Fundz

Trellis Bioscience reported raising $985,000 in an initial SEC Form D filing

PRIVATEOct 21, 2026Late filing, first sale Jun 1, 2022

Amount Raised

$985,000

$985,000 sold, per SEC Form D (first sale Jun 1, 2022)

Round Type

Venture

Redwood CityBiotechnologyHealth Care

Who else raised in Biotechnology and Health Care around the same time

Companies in the same sectors as Trellis Bioscience that raised within 45 days of this round, from Fundz verified event records.

  • PMGC Holdings Inc. raised $2.1M (Seed) on July 15, 2022.
  • Renibus Therapeutics raised $15M on July 15, 2022.
  • careviso (Formerly CMT Solutions) raised $13M on July 15, 2022.
  • BIOVIE INC. raised $6M on July 15, 2022.
  • Nucleus Genomics raised $18M (Funding Round) on July 14, 2022.
  • Greenbrook TMS raised $16M on July 14, 2022.

Who to call at Trellis Bioscience, and when

A new round usually means Trellis Bioscience is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Trellis Bioscience raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Trellis Bioscience, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Trellis Bioscience. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Trellis Bioscience

Location

Redwood City, California, United States

About

Trellis Bioscience is a clinical-stage biotechnology company focused on developing native human monoclonal antibodies (mAbs) to treat intractable infectious diseases. The company is currently advancing its investigational treatment, calpurbatug (TRL1068), for chronic prosthetic joint infections. With substantial funding from various investors, Trellis aims to redefine the treatment for antibiotic-resistant infections. They utilize innovative approaches to combat the challenges posed by bacterial biofilm in infections.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Trellis Bioscience raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsStefan, President & CEO hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Trellis Bioscience's next move

See what Strategic adds

Trellis Bioscience raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.